Cervix Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

Disease Ontology: ¹¹ A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary: Cervix Carcinoma, also known as cancer of cervix, is related to cervical cancer and cervical adenocarcinoma, and has symptoms including pelvic pain An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Cell differentiation - expanded index and miRNAs involved in DNA damage response. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include cervix uteri, cervical area and cervix.

Sources

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 420)

#	Related Disease	Score	Top Affiliating Genes
1	cervical cancer	32.4	TP53 MIR27A MIR214 MIR21 MIR200A MIR15A
2	cervical adenocarcinoma	32.4	TP53 MIR9-1 MIR362 MAPK8IP1
3	endocervical carcinoma	32.3	TP53 MAPK8IP1 H2AC18
4	endometrial adenocarcinoma	31.4	TP53 MIR200A MIR199A1
5	serous cystadenocarcinoma	30.6	TP53 MIR21 MIR199A1 H2AC18
6	glioma	30.6	TP53 MIR21 MIR15A HOXA11-AS
7	endometriosis	30.5	TP53 MIR99A MIR200A MIR199A1 MIR141
8	brain glioma	30.5	TP53 MIR218-1 H2AC18
9	peripheral nervous system disease	30.4	TP53 MIR9-1 MIR362 MIR27A MIR24-1 MIR21
10	lymphoma, hodgkin, classic	30.4	TP53 MIR9-1 MIR21 MIR200A H2AC18
11	cervix small cell carcinoma	30.4	MIR199A1 MAPK8IP1
12	tongue squamous cell carcinoma	30.4	TP53 MIR99A MIR21 MIR199A1 MIR15A MIR149
13	oral squamous cell carcinoma	30.4	MIR99A MIR9-1 MIR27A MIR24-1 MIR214 MIR21
14	bone sarcoma	30.4	TP53 MIR9-1 MIR582 MIR27A MIR214 MIR199A1
15	endometrial cancer	30.3	TP53 MIR99A MIR21 MIR200A MIR199A1 MIR141
16	leukemia, acute myeloid	30.3	TP53 MIR9-1 MIR582 MIR362 MIR27A MIR21
17	lymphoma, non-hodgkin, familial	30.3	TP53 MIR9-1 MIR27A MIR214 MIR21 MIR200A
18	wilms tumor 1	30.3	TP53 MIR27A MIR199A1 H2AC18
19	lung cancer	30.1	TP53 MIR99A MIR9-1 MIR582 MIR362 MIR27A
20	anal squamous cell carcinoma	30.0	TP53 H2AC18
21	high-grade neuroendocrine carcinoma of the cervix uteri	11.7
22	glassy cell carcinoma of the cervix uteri	11.7
23	adenoid basal carcinoma of the cervix uteri	11.4
24	primitive neuroectodermal tumor of the cervix uteri	11.4
25	cervical clear cell adenocarcinoma	11.4
26	cervical endometrioid adenocarcinoma	11.4
27	papillary carcinoma of the cervix uteri	11.4
28	suppressor of tumorigenicity 3	11.2
29	cervical adenosquamous carcinoma	11.2
30	rare cancer of cervix uteri	11.2
31	malignant mixed epithelial and mesenchymal tumor of cervix uteri	11.2
32	cervical squamous cell carcinoma	11.1
33	exocervical carcinoma	11.0
34	cervical adenoid cystic carcinoma	11.0
35	cervical adenoid basal carcinoma	11.0
36	cervical large cell neuroendocrine carcinoma	11.0
37	cystadenocarcinoma	10.5	TP53 MIR21 MIR199A1
38	pulmonary blastoma	10.5	TP53 MIR9-1 MIR214
39	non-invasive bladder papillary urothelial neoplasm	10.5	TP53 MIR99A FGFR3
40	melanoma in congenital melanocytic nevus	10.5	TP53 MIR21 MIR199A1 H2AC18
41	ovarian clear cell carcinoma	10.5	TP53 MIR9-1 MIR21 MIR199A1 H2AC18
42	mature t-cell and nk-cell lymphoma	10.5	TP53 MIR21 MIR199A1 H2AC18
43	peripheral t-cell lymphoma	10.5	TP53 MIR21 MIR199A1 H2AC18 FGFR3
44	pleural disease	10.5	TP53 MIR21 MIR200A MIR199A1 H2AC18
45	low grade glioma	10.5	TP53 MIR9-1 MIR21 MIR199A1 H2AC18
46	central nervous system benign neoplasm	10.5	TP53 MIR9-1 MIR21 MIR199A1 H2AC18
47	human papillomavirus infectious disease	10.5	TP53 MIR21 MIR199A1 MIR149
48	oropharynx cancer	10.5	TP53 MIR99A MIR21 MIR199A1 H2AC18
49	skeletal muscle cancer	10.5	TP53 MIR9-1 MIR199A1 H2AC18
50	peripartum cardiomyopathy	10.5	MIR21 MIR199A1 MIR146A

Graphical network of the top 20 diseases related to Cervix Carcinoma:

Sources

Symptoms & Phenotypes for Cervix Carcinoma

UMLS symptoms related to Cervix Carcinoma:

pelvic pain

Sources

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 33)

#

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Carboplatin

Approved

Phase 3

41575-94-4

10339178 38904

2

Paclitaxel

Approved, Vet_approved

Phase 3

33069-62-4

36314

3

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

4

Metronidazole

Approved

Phase 2, Phase 3

443-48-1, 69198-10-3

4173

5

Gemcitabine

Approved

Phase 3

95058-81-4, 122111-03-9

60750

6

Albumin-Bound Paclitaxel

Phase 3

7

Antimitotic Agents

Phase 3

8

Tubulin Modulators

Phase 3

9

Anti-Bacterial Agents

Phase 2, Phase 3

10

Anti-Infective Agents

Phase 2, Phase 3

11

Antiprotozoal Agents

Phase 2, Phase 3

12

Antiparasitic Agents

Phase 2, Phase 3

13

Antiviral Agents

Phase 3

14

Antimetabolites

Phase 3

15

Immunosuppressive Agents

Phase 3

16

Mitomycin

Approved

Phase 2

50-07-7

5746

17

Pembrolizumab

Approved

Phase 1, Phase 2

1374853-91-4

254741536

18

Antiemetics

Phase 2

19

Immunoglobulins

Phase 1, Phase 2

20

Antibodies, Monoclonal

Phase 1, Phase 2

21

Antibodies

Phase 1, Phase 2

22

Antineoplastic Agents, Immunological

Phase 1, Phase 2

23

Immunologic Factors

Phase 1, Phase 2

24

Vaccines

Phase 1, Phase 2

25

Pancrelipase

Approved, Investigational

53608-75-6

8519

26

Proflavine

Approved

92-62-6

7099

27

Liver Extracts

28

Pancreatin

29

Pharmaceutical Solutions

30

Anti-Infective Agents, Local

31

Fluorodeoxyglucose F18

32

Aluminum hydroxide, magnesium hydroxide, simethicone drug combination

33

TEMPO

Interventional clinical trials:

(show all 37)

#	Name	Status	NCT ID	Phase	Drugs
1	Assessment of the Impact of Preoperative Stress Reduction on Psychological, Physiological and Immunological Parameters in Women With Gynecological Malignancies - Prospective Randomized Controlled Trial	Unknown status	NCT00726635	Phase 3
2	A Prospective Randomized Trial of Neoadjuvant Chemotherapy and Surgery Versus Concurrent Chemoradiation Therapy in Patients With Stage IB2-IIB Squamous Carcinoma of the Uterine Cervix	Unknown status	NCT00193739	Phase 3	NACT;Inj.Cisplatin
3	A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago	Completed	NCT01937650	Phase 2, Phase 3	Radiotherapy plus metronidazole
4	Prevention and Control of Neoplasms Associated With HPV in High-risk Groups in Mexico City: The Condesa Study	Completed	NCT05149248	Phase 2, Phase 3
5	Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA	Completed	NCT00191100	Phase 3	Gemcitabine;Cisplatin
6	High Dose Rate (HDR) Versus Low Dose Rate (LDR) Brachytherapy in Carcinoma Cervix	Completed	NCT00193830	Phase 3
7	Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial	Completed	NCT02765919	Phase 3
8	An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix	Unknown status	NCT02492503	Phase 1, Phase 2	Paclitaxel and carboplatin
9	Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial)	Unknown status	NCT02879214	Phase 2
10	A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease	Unknown status	NCT03101995	Phase 2	Gemcitabine
11	Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression	Completed	NCT02309658	Phase 2	gemcitabine;cisplatin
12	A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.	Recruiting	NCT04652076	Phase 1, Phase 2	NP137;Pembrolizumab;Paclitaxel;Carboplatin
13	A Safety Lead in Single Arm Phase II Study for Image Guided Ultrafractionated Radiation Therapy for Treatment of Metastatic Cervical Cancer	Recruiting	NCT05021237	Phase 2
14	A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients	Active, not recruiting	NCT02865135	Phase 1, Phase 2	DPX-E7 vaccine
15	A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC)	Withdrawn	NCT03834571	Phase 2	Carboplatin;Cisplatin;Paclitaxel
16	A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors	Withdrawn	NCT02312804	Phase 1	BGJ398;Carboplatin;Paclitaxel
17	Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation	Unknown status	NCT01049100
18	A Nonrandomized, Non-double Blinded Prospective Cohort Study to Evaluate the Preventive Efficacy of Quadrivalent HPV6/11/16/18 Vaccine for the Persistent Infection of HPV16 Genotype or HPV18 Genotype in Japanese Women Aged 27-45 Years.	Unknown status	NCT04022148
19	The Correlation Between the Haplotype of Human Leukocyte Antigen (HLA) and Human Papillomavirus	Unknown status	NCT00154479
20	Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)	Unknown status	NCT03133286
21	Algorithm for Cervix Carcinoma Screening in the Czech Republic Using the Detection of HPV DNA With Selective HPV 16/18 Genotype and Special CINtec Plus Cytological Colouring	Completed	NCT05578833
22	Vaginal Length, Elasticity, Lubrication And Sexual Function In Women With Stage IB2 Cervix Carcinoma	Completed	NCT00053261
23	Predicting Outcome in Cervix Carcinoma: a Prospective Study	Completed	NCT01825005
24	A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy	Completed	NCT01991808
25	Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study	Completed	NCT01759355
26	Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix	Completed	NCT02206048		Proflavine
27	A Phase II Randomized Trial Comparing Intensity Modulated Radiation Therapy (IMRT) With Conventional Radiation Therapy in Stage IIB Carcinoma Cervix	Completed	NCT00193804
28	Concomitant Chemo-radiation in Advanced Stage Carcinoma Cervix: A Phase III Randomized Trial	Completed	NCT00193791
29	Para-Aortic Lymph Nodal Staging and Evaluation of Treatment Outcome by 18F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Advanced Cervical Cancer	Completed	NCT00193752
30	Histopathological Findings in Symptomatizing Patients After Supracervical Hysterectomy	Completed	NCT04809727
31	High Intensity Interval Training (HIIT) on Stationary Bike With and Without Compression Stockings for Patients With Cancer-related Lymphedema in the Lower Limbs - a Feasibility Study	Completed	NCT03653819
32	Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation	Recruiting	NCT04626466
33	The PIONEER Initiative: Precision Insights On N-of-1 Effectiveness Research. Tissue Ownership by the Individual With the Return of Actionable Information to the Individual Patient and Physician (Precision Oncology)	Recruiting	NCT03896958
34	Tempus Priority Study: An Observational Study of Patients Who Have Received Comprehensive Genomic Profiling	Recruiting	NCT05179824
35	SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	Recruiting	NCT03452774
36	Minimally Invasive Therapy Versus Open Radical Hysterectomy (MITOR) for Management of Early Stage Cervical Cancer	Not yet recruiting	NCT04999696
37	Study Evaluating Predictive Value of Local Control at 19.8 (MRI and TEP Scan) for Patient With Stade I to IIIB Cervix Carcinoma Treated by Radiotherapy	Terminated	NCT01641484

Search NIH Clinical Center for Cervix Carcinoma

Sources

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

#	Genetic test	Affiliating Genes
1	Cancer of Cervix ²⁸	FGFR3
2	Carcinoma of Cervix ²⁸

Sources

Anatomical Context for Cervix Carcinoma

Organs/tissues related to Cervix Carcinoma:

FMA: Cervix Uteri, Cervical Area

MalaCards : Cervix, Lymph Node, Bone, Liver, Uterus, Breast, Bone Marrow

Sources

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show top 50) (show all 2555)

#	Title	Authors	PMID	Year
1	Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. ⁵	Logie A...Radvanyi F	15772091	2005
2	Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. ⁵	Cappellen D...Radvanyi F	10471491	1999
3	Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I. ⁵	Tavormina PL...Wasmuth JJ	8589699	1995
4	Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumours. ⁵	Crook T...Vousden KH	1349102	1992
5	Mutational hotspot in the p53 gene in human hepatocellular carcinomas. ⁵	Hsu IC...Harris CC	1849234	1991
6	Biomarker Expression Profiling in Cervix Carcinoma Biopsies Unravels WT1 as a Target of Artesunate. ⁶²	Saeed MEM...Efferth T	36316038	2022
7	Microbes in gynecologic cancers: Causes or consequences and therapeutic potential. ⁶²	Wahid M...Rattan R	34302959	2022
8	A study for evaluating clinical relevance of circulating cell-free DNA in cervical cancer. ⁶²	Shrivastava A...Singh SK	36412409	2022
9	Synthesis and preliminary evaluations of [18F]fluorinated pyridine-2-carboxamide derivatives for targeting PD-L1 in cancer. ⁶²	Maier P...Samnick S	36281866	2022
10	Determination and evaluation of HR-HPV genotype in different communities of Bihar, India. ⁶²	Parwez A...Ali M	36101850	2022
11	Antioxidant and cytotoxicity activities of δ-tocotrienol from the seeds of Allophylus africanus. ⁶²	Zeutsop JF...Sewald N	34852702	2022
12	Added-Value of Diffusion-Weighted Imaging (DWI) and Dynamic Contrast-Enhanced (DCE-MRI) Magnetic Resonance Imaging in the Preoperative Assessment of Cervical Cancer. ⁶²	Bhardwaj R...Sharma A	35923516	2022
13	Does diffusion weighted imaging have a prognostic value in differentiating gynecological diseases? ⁶²	Dogan F...Guldur ME	35490049	2022
14	Increased expression of squamous cell carcinoma antigen 1 and 2 in mycosis fungoides and Sézary syndrome ⁶²	Oka K...Sato S	36301759	2022
15	[Clinicopathological features of mixed cervical carcinoma with adenoid cystic pattern]. ⁶²	Li LL...Liu H	35785831	2022
16	Invasive stratified mucin-producing carcinoma of cervix: A case report. ⁶²	Zou YL...Zhang YT	35843813	2022
17	Antitumor Activity of Tubulin-Binding Agent MPC-6827 on Different Types of Cancer Cell Lines. ⁶²	Topcul MR...Cetin I	35988274	2022
18	Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial. ⁶²	Chopra S...Gupta S	35387819	2022
19	Two new triterpenoid fatty acid esters from Schefflera barteri Harms (Araliaceae)§. ⁶²	Mbougnia JFT...Sewald N	33203260	2022
20	New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: Design, synthesis, biological activities and in silico studies. ⁶²	Abd El-Wahab HAA...Aboul-Fadl T	35091290	2022
21	Soyauxinine, a New Indolopyridoquinazoline Alkaloid from the Stem Bark of Araliopsis soyauxii Engl. (Rutaceae). ⁶²	Noulala CGT...Ngadjui BT	35164367	2022
22	Influence of ligand lipophilicity in Pt(II) complexes on their antiproliferative and apoptotic activities in tumour cell lines. ⁶²	Fernandez-Delgado E...Pariente JA	34922157	2022
23	Three new iridoids from the aerial parts of Nepeta teucriifolia Willd. and antiproliferative activities of extracts. ⁶²	Eser F...Aktas E	35129012	2022
24	A Prospective Investigation of Tumor Hypoxia Imaging with 68Ga-Nitroimidazole PET/CT in Patients with Carcinoma of the Cervix Uteri and Comparison with 18F-FDG PET/CT: Correlation with Immunohistochemistry. ⁶²	Mokoala KMG...Sathekge MM	35207237	2022
25	Phototheranostics of Cervical Neoplasms with Chlorin e6 Photosensitizer. ⁶²	Gilyadova A...Reshetov I	35008375	2022
26	First report of compounds from an Ancistrocarpus species: Triterpenoids from A. densispinosus Oliv. (Malvaceae). ⁶²	Peyeino JH...Vardamides JC	32598239	2022
27	Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma. ⁶²	Song T...Yan S	35283649	2022
28	A novel cervix carcinoma biomarker: Pathological-epigenomics, integrated analysis of MethylMix algorithm and pathology for predicting response to cancer immunotherapy. ⁶²	Yu YC...Wang YD	36408176	2022
29	Dosimetric Influence of Acuros XB Dose-to-Medium and Dose-to-Water Reporting Modes on Carcinoma Cervix Using Intensity-Modulated Radiation Therapy and Volumetric RapidArc Technique. ⁶²	Kumar L...Gairola M	35548039	2022
30	Cervical Cancers: Varieties and the Lower Anogenital Squamous Terminology. ⁶²	Gadkari R...Bhatia JK	35928526	2022
31	Design, Synthesis, Spectroscopic Characterisation and In Vitro Cytostatic Evaluation of Novel Bis(coumarin-1,2,3-triazolyl)benzenes and Hybrid Coumarin-1,2,3-triazolyl-aryl Derivatives. ⁶²	Prsir K...Kristafor S	35163905	2022
32	Evolution in endoscopic endonasal approach for the management of hypothalamic-pituitary region metastasis: A single-institution experience. ⁶²	Baiano C...Solari D	35965539	2022
33	Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer. ⁶²	Narva SI...Hietanen S	34619699	2021
34	How to predict para-aortic node involvement in advanced cervical cancer? Development of a predictive score. A FRANCOGYN study. ⁶²	Nguyen-Xuan HT...Huchon C	34274203	2021
35	Morbidity following image-guided brachytherapy for cervical cancer: Patient and treatment related factors. ⁶²	Jennifer LG...Marlon S	34380591	2021
36	Meleagrin from marine fungus Emericella dentata Nq45: crystal structure and diverse biological activity studies. ⁶²	Hamed A...Shaaban M	32189530	2021
37	New cyclopeptide alkaloids from the whole plant of Justicia procumbens L. ⁶²	Lv JP...Jin H	32347116	2021
38	Onosma mutabilis: Phytochemical composition, antioxidant, cytotoxicity, and acute oral toxicity. ⁶²	Jabbar AA	34646543	2021
39	Cytotoxic Effect In Vitro of Acalypha monostachya Extracts over Human Tumor Cell Lines. ⁶²	Guillen-Melendez GA...Soto-Dominguez A	34834687	2021
40	Self-Assembly and Multifaceted Bioactivity of a Silver(I) Quinolinate Coordination Polymer. ⁶²	Jaros SW...Smolenski P	34546735	2021
41	Isolated cystic liver metastasis in a case of squamous cell carcinoma of cervix. ⁶²	Ates OF...Kayra E	33624562	2021
42	MRI accuracy and interobserver agreement in locally advanced cervix carcinoma. ⁶²	Jacquot A...Etievent G	34233471	2021
43	Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria. ⁶²	Haesen J...Vergote I	34253389	2021
44	A Multicomponent Protocol for the Synthesis of Highly Functionalized γ-Lactam Derivatives and Their Applications as Antiproliferative Agents. ⁶²	Del Corte X...Vicario J	34451879	2021
45	Risk for second bladder and rectal malignancies from cervical cancer irradiation. ⁶²	Mazonakis M...Damilakis J	34021692	2021
46	Distribution of High-risk Human Papillomavirus Genotypes in Cervical Secretions in Punjab. ⁶²	Minhas S...Ansari F	34271777	2021
47	Lifetime radiation-induced sarcoma risk in patients subjected to IMRT or VMAT for uterine cervix carcinoma. ⁶²	Mazonakis M...Damilakis J	33909230	2021
48	Survival in Cervical Cancer and Its Predictors at Ocean Road Cancer Institute From January to December 2012. ⁶²	Khamis SI...Lugina EL	34010012	2021
49	Effects of Colchicum baytopiorum leaf extract on cytotoxicity and cell death pathways in C-4 I and Vero cell lines. ⁶²	Dagdeviren Ozsoylemez O...Ozcan G	34268982	2021
50	[Clear Cell Carcinoma of Cervix in a 12-Year-Old Girl: A Case Report]. ⁶²	Liu J...Liu H	34018378	2021

Sources

Genes for Cervix Carcinoma

Genes related to Cervix Carcinoma (2 elite genes):

(show top 50) (show all 81)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	504.92	Pathogenic ⁵ Genetic Tests ²⁸ DISEASES inferred ¹⁴	8589699 10471491 15772091
2	TP53	Tumor Protein P53	Protein Coding	407.25	Pathogenic ⁵ DISEASES inferred ¹⁴	1849234 1349102
3	HOXA11-AS	HOXA11 Antisense RNA	RNA Gene	153.01	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴	26054679
4	MIR362	MicroRNA 362	RNA Gene	8.6	DISEASES inferred ¹⁴ ¹⁴
5	MIR21	MicroRNA 21	RNA Gene	8.18	DISEASES inferred ¹⁴ ¹⁴
6	MIR141	MicroRNA 141	RNA Gene	7.94	DISEASES inferred ¹⁴ ¹⁴
7	MIR199A1	MicroRNA 199a-1	RNA Gene	7.92	DISEASES inferred ¹⁴ ¹⁴
8	H2AC18	H2A Clustered Histone 18	Protein Coding	7.87	DISEASES inferred ¹⁴ ¹⁴
9	MIR24-1	MicroRNA 24-1	RNA Gene	7.85	DISEASES inferred ¹⁴ ¹⁴
10	MIR218-1	MicroRNA 218-1	RNA Gene	7.84	DISEASES inferred ¹⁴ ¹⁴
11	MIR149	MicroRNA 149	RNA Gene	7.74	DISEASES inferred ¹⁴ ¹⁴
12	MIR200A	MicroRNA 200a	RNA Gene	7.72	DISEASES inferred ¹⁴ ¹⁴
13	MIR9-1	MicroRNA 9-1	RNA Gene	7.62	DISEASES inferred ¹⁴ ¹⁴
14	MAPK8IP1	Mitogen-Activated Protein Kinase 8 Interacting Protein 1	Protein Coding	7.6	DISEASES inferred ¹⁴
15	MIR27A	MicroRNA 27a	RNA Gene	7.59	DISEASES inferred ¹⁴ ¹⁴
16	MIR146A	MicroRNA 146a	RNA Gene	7.48	DISEASES inferred ¹⁴ ¹⁴
17	MIR214	MicroRNA 214	RNA Gene	7.39	DISEASES inferred ¹⁴ ¹⁴
18	MIR99A	MicroRNA 99a	RNA Gene	7.36	DISEASES inferred ¹⁴ ¹⁴
19	MIR15A	MicroRNA 15a	RNA Gene	7.25	DISEASES inferred ¹⁴ ¹⁴
20	MIR582	MicroRNA 582	RNA Gene	7.21	DISEASES inferred ¹⁴ ¹⁴
21	MIR1914	MicroRNA 1914	RNA Gene	7.21	DISEASES inferred ¹⁴ ¹⁴
22	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	7.18	DISEASES inferred ¹⁴
23	MIR15B	MicroRNA 15b	RNA Gene	7.15	DISEASES inferred ¹⁴ ¹⁴
24	MIR142	MicroRNA 142	RNA Gene	7.02	DISEASES inferred ¹⁴ ¹⁴
25	MIR196A1	MicroRNA 196a-1	RNA Gene	6.99	DISEASES inferred ¹⁴ ¹⁴
26	MIR423	MicroRNA 423	RNA Gene	6.92	DISEASES inferred ¹⁴ ¹⁴
27	STYK1	Serine/Threonine/Tyrosine Kinase 1	Protein Coding	6.87	GeneCards inferred via : Expressions (show sections)
28	MIR30A	MicroRNA 30a	RNA Gene	6.85	DISEASES inferred ¹⁴ ¹⁴
29	MIR140	MicroRNA 140	RNA Gene	6.83	DISEASES inferred ¹⁴ ¹⁴
30	MIR215	MicroRNA 215	RNA Gene	6.8	DISEASES inferred ¹⁴ ¹⁴
31	MIR186	MicroRNA 186	RNA Gene	6.73	DISEASES inferred ¹⁴ ¹⁴
32	MIR139	MicroRNA 139	RNA Gene	6.73	DISEASES inferred ¹⁴ ¹⁴
33	MIR127	MicroRNA 127	RNA Gene	6.72	DISEASES inferred ¹⁴ ¹⁴
34	MIR653	MicroRNA 653	RNA Gene	6.69	DISEASES inferred ¹⁴ ¹⁴
35	MIR330	MicroRNA 330	RNA Gene	6.68	DISEASES inferred ¹⁴ ¹⁴
36	INSM1	INSM Transcriptional Repressor 1	Protein Coding	6.59	DISEASES inferred ¹⁴
37	MIRLET7D	MicroRNA Let-7d	RNA Gene	6.59	DISEASES inferred ¹⁴ ¹⁴
38	MIR34C	MicroRNA 34c	RNA Gene	6.58	DISEASES inferred ¹⁴ ¹⁴
39	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	6.46	DISEASES inferred ¹⁴
40	CTNNB1	Catenin Beta 1	Protein Coding	6.45	DISEASES inferred ¹⁴
41	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.39	DISEASES inferred ¹⁴
42	MIR624	MicroRNA 624	RNA Gene	6.39	DISEASES inferred ¹⁴ ¹⁴
43	MIRLET7E	MicroRNA Let-7e	RNA Gene	6.39	DISEASES inferred ¹⁴ ¹⁴
44	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.33	DISEASES inferred ¹⁴
45	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	6.3	DISEASES inferred ¹⁴ ¹⁴
46	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.27	DISEASES inferred ¹⁴
47	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.26	DISEASES inferred ¹⁴
48	PTPRN	Protein Tyrosine Phosphatase Receptor Type N	Protein Coding	6.25	DISEASES inferred ¹⁴
49	SLC25A16	Solute Carrier Family 25 Member 16	Protein Coding	6.24	DISEASES inferred ¹⁴
50	CD274	CD274 Molecule	Protein Coding	6.24	DISEASES inferred ¹⁴

Sources

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

⁵ (show all 12)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	TP53	NM_000546.6(TP53):c.747G>T (p.Arg249Ser)	SNV	Pathogenic	12352	rs28934571	GRCh37: 17:7577534-7577534 GRCh38: 17:7674216-7674216
2	FGFR3	NM_000142.5(FGFR3):c.746C>G (p.Ser249Cys)	SNV	Pathogenic Pathogenic	16339	rs121913483	GRCh37: 4:1803568-1803568 GRCh38: 4:1801841-1801841
3	FGFR3	NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys)	SNV	Pathogenic Pathogenic	16332	rs121913482	GRCh37: 4:1803564-1803564 GRCh38: 4:1801837-1801837
4	FGFR3	NM_000142.5(FGFR3):c.1138G>A (p.Gly380Arg)	SNV	Pathogenic	16327	rs28931614	GRCh37: 4:1806119-1806119 GRCh38: 4:1804392-1804392
5	FGFR3	NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys)	SNV	Pathogenic	16338	rs28933068	GRCh37: 4:1807371-1807371 GRCh38: 4:1805644-1805644
6	FGFR3	NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr)	SNV	Pathogenic	65855	rs121913105	GRCh37: 4:1807890-1807890 GRCh38: 4:1806163-1806163
7	FGFR3	NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg)	SNV	Pathogenic	16340	rs4647924	GRCh37: 4:1803571-1803571 GRCh38: 4:1801844-1801844
8	FGFR3	NM_000142.5(FGFR3):c.1960-16T>C	SNV	Uncertain Significance	931624	rs1721900734	GRCh37: 4:1807968-1807968 GRCh38: 4:1806241-1806241
9	FGFR3	NM_000142.5(FGFR3):c.1993G>T (p.Ala665Ser)	SNV	Uncertain Significance	465350	rs764892330	GRCh37: 4:1808017-1808017 GRCh38: 4:1806290-1806290
10	FGFR3	NM_000142.5(FGFR3):c.2153A>G (p.Asn718Ser)	SNV	Uncertain Significance	521225	rs139773438	GRCh37: 4:1808395-1808395 GRCh38: 4:1806668-1806668
11	FGFR3	NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp)	SNV	Uncertain Significance	546226	rs369232922	GRCh37: 4:1801071-1801071 GRCh38: 4:1799344-1799344
12	BRIP1	NM_032043.3(BRIP1):c.587A>G (p.Asn196Ser)	SNV	Likely Benign	128194	rs550707862	GRCh37: 17:59924502-59924502 GRCh38: 17:61847141-61847141

Sources

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Sources

Pathways for Cervix Carcinoma

Pathways related to Cervix Carcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.4	MIR9-1 MIR214 MIR199A1
2	miRNAs involved in DNA damage response ⁷⁴	11.28	TP53 MIR27A MIR21 MIR15A
3	miRNAs involvement in the immune response in sepsis ⁷⁴	11.05	MIR9-1 MIR21 MIR199A1 MIR149
4	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	10.7	MIR27A MIR24-1 MIR214 MIR21 MIR146A
5	ncRNAs involved in STAT3 signaling in hepatocellular carcinoma ⁷⁴	10.62	MIR21 MIR200A
6	MicroRNA network associated with chronic lymphocytic leukemia ⁷⁴	10.03	TP53 MIR15A

Sources

GO Terms for Cervix Carcinoma

Cellular components related to Cervix Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.8	MIR99A MIR9-1 MIR582 MIR362 MIR27A MIR24-1
2	extracellular vesicle	GO:1903561	9.43	MIR99A MIR27A MIR24-1 MIR214 MIR21 MIR15A

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

(show all 26)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell population proliferation	GO:0008285	10.11	TP53 MIR9-1 MIR24-1 MIR218-1 MIR214 MIR21
2	positive regulation of apoptotic process	GO:0043065	10.09	TP53 MIR27A MIR21 MIR15A MIR146A
3	negative regulation of gene expression	GO:0010629	9.91	TP53 MIR9-1 MIR27A MIR214 MIR21 MIR199A1
4	negative regulation of inflammatory response	GO:0050728	9.89	MIR199A1 MIR15A MIR149 MIR146A MIR141
5	negative regulation of angiogenesis	GO:0016525	9.85	MIR24-1 MIR214 MIR21 MIR15A MIR146A
6	negative regulation of cell migration	GO:0030336	9.85	MIR9-1 MIR24-1 MIR218-1 MIR214 MIR21 MIR149
7	negative regulation of glial cell proliferation	GO:0060253	9.8	TP53 MIR146A
8	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.78	MIR27A MIR214 MIR21 MIR146A
9	miRNA-mediated gene silencing	GO:0035195	9.77	MIR99A MIR9-1 MIR582 MIR362 MIR27A MIR24-1
10	negative regulation of vascular associated smooth muscle cell proliferation	GO:1904706	9.76	MIR362 MIR214 MIR15A
11	negative regulation of cardiac muscle cell apoptotic process	GO:0010667	9.73	MIR24-1 MIR21 MIR199A1
12	negative regulation of NIK/NF-kappaB signaling	GO:1901223	9.73	MIR146A MIR149 MIR21 MIR9-1
13	negative regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	GO:1903588	9.72	MIR149 MIR15A MIR24-1
14	positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis	GO:1903589	9.71	MIR27A MIR21 MIR146A
15	negative regulation of cell migration involved in sprouting angiogenesis	GO:0090051	9.71	MIR199A1 MIR15A MIR149 MIR146A
16	negative regulation of vascular endothelial growth factor production	GO:1904046	9.7	MIR199A1 MIR15A MIR146A
17	cell growth involved in cardiac muscle cell development	GO:0061049	9.63	MIR24-1 MIR199A1
18	positive regulation of connective tissue replacement	GO:1905205	9.62	MIR214 MIR199A1
19	miRNA-mediated gene silencing by mRNA destabilization	GO:0035279	9.62	MIR9-1 MIR27A MIR214 MIR146A
20	negative regulation of interleukin-1-mediated signaling pathway	GO:2000660	9.61	MIR27A MIR21
21	negative regulation of receptor signaling pathway via STAT	GO:1904893	9.6	MIR99A MIR149
22	positive regulation of cardiac muscle hypertrophy in response to stress	GO:1903244	9.59	MIR214 MIR199A1
23	negative regulation of leukocyte adhesion to vascular endothelial cell	GO:1904995	9.58	MIR146A MIR141
24	negative regulation of matrix metallopeptidase secretion	GO:1904465	9.57	MIR199A1 MIR146A
25	negative regulation of vascular associated smooth muscle cell migration	GO:1904753	9.55	MIR362 MIR218-1 MIR214 MIR21 MIR15A
26	miRNA-mediated gene silencing by inhibition of translation	GO:0035278	9.5	MIR146A MIR15A MIR21 MIR218-1 MIR24-1 MIR27A

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA 3'-UTR binding	GO:0003730	9.7	TP53 MIR9-1 MIR27A MIR24-1 MIR214 MIR21
2	mRNA base-pairing translational repressor activity	GO:1903231	9.5	MIR99A MIR9-1 MIR582 MIR362 MIR27A MIR24-1

Sources

Sources for Cervix Carcinoma

¹ BitterDB

² CDC

³ Cell Signaling Technology

⁴ ClinicalTrials

⁵ ClinVar

⁶ CNVD

⁷ Cochrane Library

⁸ Cosmic

⁹ dbSNP

¹⁰ DGIdb

¹¹ Disease Ontology

¹² diseasecard

¹³ DiseaseEnhancer

¹⁴ DISEASES

¹⁵ DrugBank

¹⁶ EFO

¹⁷ ExPASy

¹⁸ FMA

¹⁹ GARD

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ GenomeRNAi

²⁶ GEO DataSets

²⁷ GO

²⁸ GTR

²⁹ HMDB

³⁰ HPO

³¹ ICD10

³² ICD10 via Orphanet

³³ ICD11

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ LifeMap

³⁷ LncRNADisease

³⁸ LOVD

³⁹ MalaCards

⁴⁰ MedGen

⁴¹ MedlinePlus

⁴² MedlinePlus Genetics

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NINDS

⁵³ Novoseek

⁵⁴ Novus Biologicals

⁵⁵ ODiseA

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 08-Dec-2022)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubChem

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ WikiPathways

⁷⁵ Wikipedia

MCID: CRV040 MIFTS: 50	Cervix Carcinoma Categories: Cancer diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables